Close Menu

SiMoA

Quanterix this week launched a commercial, research-use-only version of its Single Molecule Array, Simoa, platform.

Quanterix and BioMérieux recently announced a partnership giving BioMérieux worldwide exclusive rights to Quanterix's Single Molecule Array, or SiMoA, technology for clinical assay development and industrial applications.

Quanterix is now "shifting from an R&D phase to a commercial phase" as it prepares to launch its Simoa platform next year.

By Adam Bonislawski
Scientists at the Forsyth Institute, Beth Israel Deaconess Medical Center, and biomarker firm Quanterix announced this week a collaboration to evaluate protein biomarkers for tuberculosis.

Quanterix said this week that it has received an investment of an undisclosed amount from In-Q-Tel, a non-profit investment firm that delivers technology to the US intelligence community.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The firm is currently developing a research-use-only version of the instrument that it expects to launch in 2013 with an FDA-approved version coming sometime after that. It plans to manufacture the RUO device through an outside vendor because most of its parts are off-the-shelf.

Pages

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.